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ABSTRACT  
Introduction: In the recent years, uterine artery embolisation (UAE) has been gaining 
increasing popularity as an effective and minimally invasive treatment for uterine fibroids. 
However, there has been a growing concern over the risk of unintended embolization of the 
utero-ovarian circulation leading to reduction of ovarian blood supply with subsequent 
impairment of ovarian reserve. The purpose of this study was to investigate the impact of 
UAE on circulating anti-Müllerian hormone (AMH) and other markers of ovarian reserve. 
Material and methods: This meta-analysis included all published cohort, cross-sectional and 
case-control studies a well as randomized trials that investigated the impact of UAE on 
circulating AMH. Data sources included MEDLINE, EMBASE, Dynamed Plus, 
ScienceDirect, TRIP database, ClinicalTrials.gov and the Cochrane Library from January 
2000 to June 2019. All identified articles were screened, and articles were selected based on 
the inclusion and exclusion criteria. AMH and other data were extracted from the eligible 
articles and entered into RevMan software to calculate the weighted mean difference between 
pre- and post-embolization values. PROSPERO registration number: CRD42017082615. 
Results: This review included three cohort and three case-control studies (n=353). The 
duration of follow up after UAE ranged between three and 12 months. Overall pooled 
analysis of all studies showed no significant effect of UAE on serum AMH levels (weighted 
mean difference -0.58 ng/ml; 95% CI -1.5 to 0.36, I
2
=95%). Subgroup analysis according to 
age of participants (under and over 40 years) and according to follow-up duration (3, 6 and 
12-month) showed no significant change in post-embolization circulating AMH. Pooled 
analysis of serum follicle stimulating hormone (FSH) concentrations (four studies, n=248) 
revealed no statistically significant change after UAE (weighted mean difference 4.32; 95% 
CI -0.53 to 9.17; I2= 95%).  Analysis of two studies (n=62) measuring antral follicle count 
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showed a significant decline at 3-months follow up (weighted mean difference -3.28; 95% CI 
-5.62 to -0.93; I
2
= 94%). Conclusions: Uterine artery embolization for uterine fibroids does 
not seem to affect ovarian reserve as measured by serum concentrations of AMH and FSH. 
 
Keywords:  
Uterine artery embolization; Ovarian reserve; Anti-Müllerian Hormone; Antral Follicle 
Count; follicle stimulating hormone 
 
Abbreviations:  
AFC, antral follicle count;  
AMH anti-Müllerian hormone 
FSH, follicle stimulating hormone,  
UAE, uterine artery embolization;  
WMD weighted mean difference 
 
Key message: 
This systematic review analysed six studies investigating the effect of uterine artery 
embolization on ovarian reserve in 353 women. Ovarian reserve was determined by 
circulating anti-Müllerian hormone. The review found that this procedure had no detrimental 
effect on ovarian reserve.    
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INTRODUCTION 
Uterine fibroids are the most common benign pelvic neoplasm in women with a wide 
variation in reported prevalence (25% - 80%) in the literature.
1,2
 The wide variation in 
prevalence of fibroids is due to differences in populations (age, race, etc.) studied.
3
 Although 
the majority are asymptomatic, about 25% of women with fibroids have symptoms that 
significantly impact on their quality of life such as menorrhagia, dysmenorrhoea, bloating, 
pressure symptoms and fatigue (1). Other reproductive problems include subfertility or 
adverse pregnancy outcome depending on the location, size and number of the fibroids.
4
 
Treatment options for uterine fibroids include, expectant management, symptomatic 
treatment, hormonal therapy, hysteroscopic resection, myomectomy, hysterectomy and 
uterine artery embolization (UAE).  
UAE was first introduced in 1995 as a minimally invasive and uterine sparing treatment 
option for premenopausal women with symptomatic fibroids.
5
 Since then, UAE has been 
successfully employed in the management of other obstetric and gynecologic problems such 
as adenomyosis,
6
 uterine vascular malformations
7
 and postpartum haemorrhage.
8
 
Furthermore, health-related quality of life results following UAE were reported to be 
comparable to hysterectomy.
9
  
The procedure is performed utilizing a percutaneous transfemoral approach to access both 
internal iliac arteries. After confirming the position of the catheter in the internal iliac artery, 
a guide wire is fed into the uterine artery and the catheter is threaded over the guide wire. 
After that, angiography is performed to assess the vascularity and size of the fibroid before 
the embolic agent is injected.
10
 The reported improvement in menorrhagia, pelvic pain, pelvic 
pressure after UAE is 90%, 80% and 90% respectively.
9,11 
While UAE has been established as an effective and minimally invasive treatment option for 
uterine fibroids, there have been concerns over its impact on ovarian reserve in women 
desiring future pregnancy. It has been postulated that unintended embolization of the utero-
ovarian collateral circulation during UAE could lead to impairment of the blood supply to the 
ovaries with subsequent decline in ovarian reserve.
12 
To date, the impact of UAE on ovarian function in women wishing to retain fertility remains 
controversial.
12
 While some authors suggested that UAE should not be offered to women 
desiring future pregnancy,
13,14
 others reported that UAE has insignificant effect on ovarian 
reserve and should be considered a feasible treatment option for women wishing to remain 
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fertile.
15–17
 Tulandi and co-workers reported a harmful effect on ovarian reserve after UAE.
12
 
However, more recent studies utilizing anti-Müllerian hormone (AMH) as a marker for 
ovarian reserve revealed no significant decline in ovarian reserve after UAE.
18-20
 Given the 
relatively small size of these studies, further evidence is required to draw a firm conclusion. 
Therefore, the aim of this systematic review and meta-analysis was to investigate the impact 
of uterine artery embolization on ovarian reserve as determined by circulating serum AMH 
levels. 
 
MATERIAL AND METHODS 
Criteria for study selection 
This study was conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines
21
 and was prospectively registered in PROSPERO 
(CRD42017082615). All published cohort, cross-sectional, case-control studies and 
randomized controlled trials that investigated the impact of UAE on ovarian reserve as 
determined by serum AMH concentration were included in this systematic review. 
 
Outcome measures 
Primary outcome 
This included changes in serum AMH concentration after UAE.  
Secondary measures 
These included post-embolization changes in serum follicle stimulating hormone (FSH) 
concentration and antral follicle count (AFC). 
 
Search strategy 
An extensive electronic database search was performed using MEDLINE, Scopus, EMBASE, 
Dynamed, TRIP, ScienceDirect and the Cochrane library to identify published research 
articles between January 2000 and December 2018, on the impact of UAE on ovarian reserve 
as determined by serum AMH concentration. A combination of the following search terms 
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was used: uterine artery embolisation, uterine artery embolization, fibroid embolization, 
ovarian reserve, anti- Müllerian hormone, antral follicle count, ovarian volume, follicle 
stimulating hormone, ovarian function and pregnancy rate. For a more comprehensive search, 
we have also searched different databases using terms relating to the population (patients 
with fibroid) and intervention (UAE) regardless of the outcomes as recommended by 
Cochrane methodology. All searches were carried out by the first author (TE) and then 
independently repeated using the same criteria by an accredited clinical librarian (CJ). All 
relevant reports were retrieved, and their reference lists were reviewed manually to identify 
further studies. The included studies should have been published in a peer-reviewed journal, 
with full-text available in English. We also considered published abstracts from conferences. 
 
Screening and selection of studies 
All the identified papers were screened for relevance to the review by reading the title and 
abstract. Relevant studies were read in full for eligibility according to inclusion/exclusion 
criteria. They were evaluated according to a standardized format including study design, 
methods, participant characteristics, intervention, and results. Two investigators (TE & AM) 
reviewed the articles and collected the information independently. In the case of 
discrepancies in scoring between the two investigators, a consensus was reached after 
discussion or after involvement of the senior investigators (SA & KJ). 
 
Quality of included studies and risk of bias assessment 
The quality and risk of bias of the included studies were assessed using a modified 
Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies. The 
original Newcastle-Ottawa scale for nonrandomized studies assesses three main categories 
including selection, comparability, and outcomes giving a maximum of four, two, and three 
stars for each category respectively.
22
 This scale was modified to suite the nature of this study 
giving a maximum of three stars for selection, four for comparability, and two for outcome 
criteria.
23,24
 Selection was rated according to recruitment bias, selection of consecutive 
participants and power calculation. Comparability was assessed based on studies adjusting 
their analysis for four confounders including participants’’ age (<40), dominant fibroid 
volume, baseline serum AMH and laterality of the UAE procedure. Outcome was scored 
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according to completeness of at least three-month follow-up after embolisation. It is generally 
accepted that a limit of five stars could identify studies at low risk of bias.
25,26
 However, in 
our study, we have set the cut-off level at six stars.
23
 Table 1 shows the results of quality 
scores of the studies included in this analysis. 
 
Data extraction and analysis 
Pre- and post-embolization data including mean ± SD serum concentrations AMH (ng/ml) 
and FSH (IU/L) and ovarian volume were extracted from the individual studies and entered 
into Review Manager version 5.1 software -The Cochrane Collaboration, 2011 (The Nordic 
Cochrane Centre, Copenhagen, Denmark). The weighted mean difference (WMD) between 
pre- and post-embolization values was calculated.  
Statistical heterogeneity was assessed by chi-squared (χ
2
, or Chi
2
) test and I
2
 statistics. A Chi
2
 
statistic larger than its degree of freedom or an I
2
 higher than 50% was indicative of 
significant heterogeneity (moderate to high level) between studies. When heterogeneity was 
significant, a random-effect model was used for meta-analysis. Fixed effect meta-analysis 
was used when there was no significant heterogeneity.
27 
The initial analysis included data from all studies, irrespective of length of follow-up. In 
studies with multiple post-operative measurements at different follow up points, we utilized 
the latest AMH level. Further subgroup analyses of AMH levels were then performed based 
on duration of follow-up.  
 
RESULTS 
Our initial search identified a total of 131 articles, of which nine were considered relevant as 
described above (Figure 1). Our more comprehensive search including population and 
intervention regardless of the outcome identified 1977 articles. Screening of these articles 
did not reveal any more relevant studies.  
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Excluded studies  
After the initial screening on the basis of the title and abstract, 122 studies were deemed 
irrelevant to the topic of systematic review and were therefore excluded (Figure 1). Three 
further studies were excluded due to missing data, including pre- and/or post-embolization 
serum AMH levels.
28–30
 The authors of these three studies were contacted via email to 
provide the missing data but did not respond despite several reminders.  
 
Included studies 
The remaining six studies were eligible for our review and included all required data. These 
are summarized in Table 2. All studies scored ≥6 on the modified Newcastle-Ottawa scale 
and the sensitivity analysis was not carried out. 
 
Study design 
The review included two prospective cohort,
15,31
 one retrospective cohort
32
 and three case-
control studies.
19,20,33
 
 
Participants 
Selection criteria were appropriate for all studies. All studies reported inclusion and exclusion 
criteria that were appropriate except one.
19 
With regards to the laterality of UAE, five studies reported bilateral UAE and one did not 
specify the laterality.
19
 The embolic agent was polyvinyl alcohol in two studies,
15,33
 tris-acryl 
gelatin microspheres in one study,
31
 gelatin sponge particles in one study,
32
 and was not 
reported in one study.
19
 One study presented pre- and post-embolization AMH concentrations 
in median and range. We contacted the corresponding author who provided the mean±SD of 
AMH.
33 
The length of follow up was up to three months in one study,
33
 six months in one study,
19
 10 
months in one study
15
 and 12 months in three studies.
31,32,20
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UAE techniques 
Apart from one study,
19
 all other studies described the methods and the material used for 
UAE including polyvinyl alcohol particles 500 microns,
15,33
 gelatin sponge particles (500- 
710 μm, then changed to 710 – 1000 μm),
32
 spherical nonresorbable hydrogel coated 
microspheres (700 μm and 900 μm in diameter)
20
 and calibrated Tris acryl microspheres 
(>500 μm in diameter).
31
 In all these studies, one experienced interventional Radiologist 
performed the UAE bilaterally by inserting an angiographic catheter into the femoral artery 
through an incision in the right groin. Two studies described the embolization end-point as 
the complete stasis of contrast agent in the ascending segment of the uterine artery.
20,32
 One 
study defined the embolization end-point as the pruned-tree appearance corresponding to 
limited UAE targeting the peri-fibroid arterial plexus and sparing normal adjacent myometrial 
arteries.
31
 
 
AMH assays  
Only two studies provided the type of AMH kit used (without giving any details) including 
E90228Hu AMH ELISA (Uscn Life Science Inc., Wuhan, Hubei, China)
33 
and AMH 
Monobinal kit.
19 
 The remaining four studies did not specify the type AMH kit used.  
Overall pooled results for all studies 
Analysis of all six studies including 353 participants showed no significant change in post-
embolisation serum AMH concentrations (WMD -0.60 ng/ml; 95% confidence interval (CI) -
1.51 to 0.31). Heterogeneity between studies was high (I
2
 = 94 %) (Figure 2).
15,19,20,31-33
       
 
Sensitivity analysis 
No sensitivity analysis was performed as all studies scored ≥6 on the modified Newcastle-
Ottawa scale.  
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Subgroup analysis 
According to age of participants 
A total of four studies provided data for women under / over 40 years of age including two 
studies with women ≤40 years (n=50),
19,33
 one study including under 40 (n=21) and over 40 
(n=11)
32
 and one study including women over 40 (n=120).
20
 The remaining two studies 
included women with an age range crossing 40 and did not provide separate data for under / 
over 40 years of age.
15,31
  
Pooled analysis of the three studies including participants aged ≤40 years (n=71) showed no 
significant change in post embolization serum AMH concentrations (WMD -0.93; 95% CI -
2.39 to 0.53; I
2
= 91%.
19,32,33
 
Pooled analysis of the two studies including participants aged>40 years (n=131) revealed no 
significant change in post embolization serum AMH levels (WMD -0.10; 95% CI -0.92 to 
0.09; I
2
= 0%.
20,32
 
According to duration of follow up 
Pooled results of four studies (n=246) showed no significant drop in serum AMH 
concentration at three months after embolization (WMD -0.21; 95% CI -0.52 to 0.10; 
I
2
=96%).
20,31-33
 Analysis of three studies (n=204) with six months follow up showed no 
statistically significant difference in post-embolization serum AMH concentration (WMD -
0.17; 95%CL -0.43 to 0.13; I
2
=0%).
19,20,31
 Similarly, analysis of three studies (n=214) with 12 
months follow-up revealed no statistically significant difference in post-embolization serum 
AMH concentration (WMD -0.09; 95%CL -0.32 to 0.14; I
2
=0%).
20,31,32
 
 
Secondary outcomes 
Serum FSH concentrations 
Four studies measured changes in serum FSH concentrations (n=248).
20,31-33
 Pooled analysis 
of these four studies showed no significant change in circulating FSH following UAE (WMD 
4.32; 95% CI -0.53 to 9.17; I
2
= 95%) (Figure 3).  
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Antral Follicle Count  
Two studies included AFC (as a marker for ovarian reserve) as an outcome measure at three 
months follow up (n=62).
32,33
 Pooled analysis of these two studies showed a significant 
decline in AFC at three months following UAE (WMD -3.28; 95% CI -5.62 to -0.93; I
2
= 
94%) (Figure 4).  
 
DISCUSSION  
To the best of our knowledge, this is the first systematic review to investigate the impact of 
UAE on ovarian reserve as determined by serum AMH concentration. The data from our 
meta-analysis showed no significant effect of UAE on ovarian reserve as measured by AMH 
levels up to 12 months after the procedure. Subgroup analysis to evaluate the degree of effect 
on ovarian reserve at 3 and 6 months also showed no significant drop in AMH levels after 
UAE. We have adopted an extensive electronic and manual search approach and we have 
examined the quality of the included studies through a modified Newcastle-Ottawa Quality 
Assessment Scale.  
Two of the reviewed studies showed a significant reduction of AFC at three months follow-
up.
32,33
 Interestingly, one of these two studies reported a partial recovery of AFC at 12 
months follow-up.
32
 This is in agreement with a previous study by Tropeano et al who 
reported no significant change in AFC at 12-month and up-to 5 years after UAE when 
compared with a control group.
13
 Given the small number of the women included in the 
reviewed studies it is difficult to draw a firm conclusion on the short-term effect of UAE on 
AFC. A possible explanation of the observed decline in AFC could be an untargeted 
occlusion of the uterine collateral artery contributing to the ovarian blood flow as a result of 
UAE.
16
 The later increase in AFC may be due to recovery of the ovarian blood flow due to 
compensation from the ovarian artery (14).   
Pooled analyses of the secondary outcome “FSH concentration” of four studies showed no 
change in FSH level following UAE. This finding is similar to previous reports by Ahmed et 
al and Healey et al which have not demonstrated any significant impact by UAE on FSH 
levels.
34,35
 The trend of increasing FSH levels after UAE (WMD 4.32; 95% CI -0.53 to 9.17), 
albeit statistically insignificant, may be partially explained by the increased age of 
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participants in two studies including Tsikouras et al (age, 43.58±2.05 years) and Kim et al 
(age, 39.4±4.8 years).
20,32
  
The study by Czuczwar and colleagues reported a significant decrease in mean AMH levels 
from 3.4ng/ml  0.39 to 1.32ng/ml  0.81 at 3-month follow-up after UAE.
33
 This is in 
disagreemet with all the other five studies, which reported no statistically significant change 
in post-UAE AMH at 3-month follow up.
15,19,20,31,32
 When looking at the AMH data of 
Czuczwar et al, we noted that some of their participants had relatively higher baseline AMH 
levels (ranging between 5 to 7 ng/ml) compared to other reviewed studies. This high AMH 
levels could be related to high prevalence of polycystic ovary syndrome in the studied 
population. In other words, the discrepancies between this study and the other publications 
could be due to the difference in the study populations.  
The lack of any effect on ovarian reserve, as measured by AMH and FSH levels could be 
explained by the fact that UAE does not affect the utero-ovarian collateral circulation with no 
subsequent impairment of the ovarian blood supply. Another possible explanation is that any 
unintended embolization of the utero-ovarian collateral circulation during UAE does not 
cause significant compromise to the ovarian blood supply. 
Our study is limited by the small sample size of the included studies (n=353) and the high 
heterogeneity between studies. A major source of this heterogeneity is the variation in the 
operators’ experiences and UAE techniques.  It is well recognised that many technical 
factors, including embolization material type & size, extent of embolization, and 
embolization end-point, could influence the extent of arterial occlusion and the chances of 
occluding the utero-ovarian anastomosis with a potential negative impact on the ovarian 
reserve.
32,36
 For instance Kim et al explained in a previous publication that they changed the 
embolization particles to larger sizes (from 500 – 710 μm to 710 – 1000 μm) in order to avoid 
nontarget embolization of the ovarian parenchyma.
37
 They, however, admitted that the reflux 
to the utero-ovarian anastomoses was unavoidable at times when trying to achieve the 
embolization endpoints. They recommended that embolization should be aborted if this 
reflux reaches the ovarian parenchyma.  
Another important factor contributing to the heterogeneity is the variation in the age of the 
participants and the duration of the follow up in different studies. While Czuczwar et al and 
McLucas et al included women with median (range) age of 35 (33-40) years and mean (±SD) 
age of 35.5 (±3.8) years respectively,
15,33
 Tsikouras et al included women with mean (±SD) 
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age of 43.58 (±2.05) years.
20
 The mean (±SD) age of women in Kim et al, Keshavarzi et al 
and Torre et al were 39.4 (±4.8), 34.55 (±3.94) and 37.3 (±3.9) years respectively.
19,31,32
 
Therefore, further research is needed with a larger population of women less than 40 years of 
age to allow a firm conclusion on the impact of UAE on ovarian reserve. Furthermore, as 
AMH levels decline with age future studies should undertake regression analysis to 
investigate the influence of the varied ages of participants on the levels of AMH. 
Another weakness in the reviewed studies is the lack of information on the AMH kits used. 
Over the last decade, several AMH kits have been developed with a wide variation in 
sensitivities and inter- and inter-assay coefficients of variation. It is now well established that 
different AMH kits give varied results. Furthermore, inter-laboratory variations and sample 
instability further complicate the interpretation and clinical implications of AMH values. 
This review provides preliminary evidence for safety of UAE in young women wishing to 
retain their fertility. This is further supported by recent reports of successful pregnancies 
following UAE in women under 40 years old.
15,38 
However, further high-quality prospective 
randomised studies with robust designs are required to verify the findings of this review. 
 
CONCLUSION 
UAE does not seem to affect ovarian reserve, as measured by AMH and FSH levels. Given 
the low quality of studies included in this review, further research is needed with a larger 
population of women under 40 years of age to allow a firm conclusion. 
 
Acknowledgements  
We are grateful to all to all Librarians and other staff in the Library at the University 
Hospitals of Derby and Burton NHS Foundation Trust and to for their help with the literature 
search and obtaining the full text of selected articles. We are also grateful to Ms Louise 
Levitt, Librarian at Patricia Bowen Library & Knowledge Service, Chelsea and Westminster 
Hospital NHS Foundation Trust 
 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
References 
1. Laughlin SK, Stewart EA. Uterine leiomyomas: individualizing the approach to a 
heterogeneous condition. Obstet Gynecol 2011;117:396-403.  
2. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative 
incidence of uterine leiomyoma in black and white women: ultrasound evidence. 
Am J Obstet Gynecol 2003;188:100-107.  
3. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine 
leiomyoma among premenopausal women by age and race. Obstet Gynecol 
1997;90:967-973.  
4. Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding 
associated with uterine leiomyomata. Obstet Gynecol 2003;101:431-437.  
5. Ravina J, Ciraru-Vigneron N, Bouret J, et al. Arterial embolisation to treat uterine 
myomata. The Lancet 1995;346:671-672.  
6. Siskin GP, Tublin ME, Stainken BF, Dowling K, Dolen EG. Uterine artery 
embolization for the treatment of adenomyosis: clinical response and evaluation 
with MR imaging. Am J Roentgenol 2001;177:297-302.  
7. Ghai S, Rajan DK, Asch MR, Muradali D, Simons ME, TerBrugge KG. Efficacy of 
embolization in traumatic uterine vascular malformations. J Vasc Interv Radiol 
2003;14:1401-1408.  
8. Mason BA. Postpartum hemorrhage and arterial embolization. Curr Opin Obstet 
Gynecol 1998;10:475-479.  
9. de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs 
hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes 
from the randomized EMMY trial. Am J Obstet Gynecol 2016;215:745-e1.  
10. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice 
guidelines. Uterine fibroid embolization (UFE). Number 150, October 2004. Int J 
Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 2005;89:305.  
11. Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery 
embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
2 years’ outcome from the randomized EMMY trial. Am J Obstet Gynecol 
2007;196:519-e1-11.  
12. Tulandi T, Sammour A, Valenti D, Child TJ, Seti L, Tan SL. Ovarian reserve after 
uterine artery embolization for leiomyomata. Fertil Steril 2002;78:197-198.  
13. Tropeano G, Di Stasi C, Amoroso S, Gualano MR, Bonomo L, Scambia G. Long-
term effects of uterine fibroid embolization on ovarian reserve: a prospective cohort 
study. Fertil Steril 2010;94:2296-300.  
14. Kaump GR, Spies JB. The impact of uterine artery embolization on ovarian function. 
J Vasc Interv Radiol 2013;24:459-467.  
15. McLucas B, Voorhees III WD, Snyder SA. Anti-Müllerian hormone levels before and 
after uterine artery embolization. Minim Invasive Ther Allied Technol 2018;27:186-
190.  
16. Tropeano G, Amoroso S, Di Stasi C, Vizzielli G, Bonomo L, Scambia G. The timing 
of natural menopause after uterine fibroid embolization: a prospective cohort study. 
Fertil Steril 2011;96:980-984.  
17. Pisco JM, Duarte M, Bilhim T, Cirurgiao F, Oliveira AG. Pregnancy after uterine 
fibroid embolization. Fertil Steril 2011;95:1121-e5.  
18. McLucas B, Voorhees III WD, Elliott S. Fertility after uterine artery embolization: a 
review. Minim Invasive Ther Allied Technol. 2016;25:1-7.  
19. Keshavarzi F, Salehi M, Mansouri A. Comparison of anti-Mullerian hormone level 
between uterine artery embolization and myomectomy in uterine fibroma. J Med 
Life. 2015;8:54.  
20. Tsikouras P, Manav B, Koukouli Z, et al. Ovarian reserve after fibroid embolization 
in premenopausal women. Minim Invasive Ther Allied Technol 2017;26:284-291.  
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.  
22. Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane Handb 
Syst Rev Interv Cochrane Book Ser. 2008;187-241.  
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
23. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on 
ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab. 
2012;97:3146-3154.  
24. Mohamed AA, Yosef AH, James C, Al‐Hussaini TK, Bedaiwy MA, Amer SA. 
Ovarian reserve after salpingectomy: a systematic review and meta‐analysis. Acta 
Obstet Gynecol Scand. 2017;96:795-803 
25. Aziz O, Constantinides V, Tekkis PP, et al. Laparoscopic versus open surgery for 
rectal cancer: a meta-analysis. Ann Surg Oncol. 2006;13:413-424.  
26. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of 
HIV and sexually transmitted infections among men who have sex with men: a 
meta-analysis. JAMA. 2008;300:1674-1684.  
27. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 
2011;342:d549.  
28. Sasson AM, Spira M, Rahav R, et al. 54: Ovarian reserve after uterine artery 
embolization in women with morbidly adherent placenta. Am J Obstet Gynecol 
2018;218:S41.  
29. Hehenkamp WJ, Volkers NA, Broekmans FJ, et al. Loss of ovarian reserve after 
uterine artery embolization: a randomized comparison with hysterectomy. Hum 
Reprod 2007;22:1996-2005.  
30. Powell M, Chandrasena A. The effect of uterine artery embolisation on anti-mullerian 
hormone levels. London: Springer-Verlag; 2011.  
31. Torre A, Paillusson B, Fain V, Labauge P, Pelage J, Fauconnier A. Uterine artery 
embolization for severe symptomatic fibroids: effects on fertility and symptoms. 
Hum Reprod 2014;29:490-501.  
32. Kim C-W, Shim HS, Jang H, Song YG. The effects of uterine artery embolization on 
ovarian reserve. Eur J Obstet Gynecol Reprod Biol 2016;206:172-176.  
33. Czuczwar P, Stepniak A, Milart P, Paszkowski T, Wozniak S. Comparison of the 
influence of three fibroid treatment options: supracervical hysterectomy, ulipristal 
acetate and uterine artery embolization on ovarian reserve–an observational study. J 
Ovarian Res 2018;11:45.  
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
34. Ahmad A, Qadan L, Hassan N, Najarian K. Uterine artery embolization for treatment 
of uterine fibroids: Effect on ovarian function in younger women. J Vasc Interv 
Radiol 2002;13:1017-1020.  
35. Healey S, Buzaglo K, Seti L, Valenti D, Tulandi T. Ovarian function after uterine 
artery embolization and hysterectomy. J Am Assoc Gynecol Laparosc 2004;11:348-
352.  
36. Razavi MK, Wolanske K A, Hwang G L, Sze DY, Kee ST, Dake MD. Angiographic 
classification of ovarian artery-to-uterine artery anastomoses: initial observations in 
uterine fibroid embolization. Radiology 2002;224:707–712. 
37. Kim HS, Tsai J, Lee JM, Vang R, Griffith JG, Wallach EE. Effects of utero-ovarian 
anastomoses on basal follicle-stimulating hormone level change after uterine artery 
embolization with tris-acryl gelatin microspheres. J Vasc Interv Radiol. 
2006;17:965-971. 
38. Torre A, Fauconnier A, Kahn V, Limot O, Bussierres L, Pelage JP. Fertility after 
uterine artery embolization for symptomatic multiple fibroids with no other 
infertility factors. Eur Radiol 2017;27:2850-2859.  
 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Figure and table legends  
 
Table 1. The results of quality scores of the studies included in the analysis 
 
Table 2. Characteristics of the six studies included in the meta-analysis. 
 
Figure 1. PRISMA Flow Chart of the study selection process 
 
Figure 2. Weighted mean difference in serum anti-Müllerian hormone concentrations after 
uterine artery embolization for symptomatic uterine fibroids: pooled results for all six studies 
 
Figure 3. Weighted mean difference in serum follicle stimulating hormone concentrations 
after uterine artery embolization for symptomatic uterine fibroids: pooled results for four 
studies 
 
Figure 4. Weighted mean difference in antral follicle count after uterine artery embolization 
for symptomatic uterine fibroids: pooled results for two studies 
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Table 1. The results of quality scores of the studies included in the analysis 
 
Author Year Selection Comparability Outcome Score 
Torre et al (31) 2014 ** *** ** 7 
Keshavarzi et al 
(19) 
2015 ** ** ** 6 
Kim et al (32) 2016 * *** ** 6 
McLucas et al (15) 2017 ** ** ** 6 
Tsikouras et al (20) 2017 ** *** ** 6 
Czuczwar et al (33) 2018 * **** ** 7 
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Table 2. Characteristics of the six studies included in the meta-analysis. 
 
* fist follow up was 2 weeks after surgery 
** gelatin sponge 500-710µm then changed to 710-1000µm 
*** 190±290 days 
NS, Not specified; PVA, polyvinyl alcohol; AMH anti-Müllerian hormone; FSH follicle stimulating hormone; LH, luteinising hormone; E2 
oestradiol; AFC, antral follicle count; OV, ovarian volume; ELISA, Enzyme-linked Immunosorbent Assay 
 
Author Country Design n 
Age 
(mean±SD) 
Laterality &  
method of UAE 
Dominant 
fibroid volume 
(ml) 
Follow up 
(Months) 
AMH Kit 
Secondary outcomes 
(ovarian reserve 
markers) 
Torre et al., 2014 (31) France Prospective 
Cohort 
64 37.3±3.9 Bilateral (Tris acryl 
microspheres 500-1200µm) 
97±103 3, 6, 12*  NS FSH, LH, E2, Inhibin B, 
fertility 
Keshavarzi et al., 2015 
(19) 
Iran Case-control 20 34.6±3.9 NS NS 6  
Monobinal 
kit 
- 
Kim et al.,2016 (32) South 
Korea 
Retrospective 
Cohort 
32 39.4±4.8 Bilateral (gelatin sponge) 
**  
265.26±339.0 3, 12 NS FSH, LH, E2, AFC, OV 
McLucas et al., 2017 (15) USA Prospective 
Cohort 
87 35.5±3.8 Bilateral (PVA ≥500µm) NS Variable*** NS - 
Tsikouras et al., 2017 (20) Greece Case-control 120 43.6±2.05 Bilateral (Hydrogel coated 
microspheres 700µm- 
900µm) 
NS 1, 3, 6, 12  NS FSH, LH, E2 
Czuczwar et al.,2018 (33) Poland Case-control 30 35 (33-40) Bilateral (PVA)  108.5±12.6 3  ELISA 
(USCN-
E90228Hu 
FSH, AFC, inhibin B, 
E2 
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